Skip to main
  1. Stocks
  2. Rapport Therapeutics Inc
  3. Forecast
RAPP

RAPP Stock Forecast & Price Target

RAPP Analyst Ratings

Based on 9 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Rapport Therapeutics is attractive because RAP-219 has already established proof of concept in bipolar mania with statistically significant efficacy and a differentiated tolerability profile, including placebo-parity adverse events, no serious adverse events, and low discontinuation rates. The company’s 3Q26 execution also improved confidence in its pipeline, as FOCUS 1/2 continued enrolling, the RAP-641 IND was cleared, and pro-forma cash rose to $815.4M after raising about $420.7M, extending runway to YE29. With pivotal and late-stage catalysts spanning 4Q26 to 2H27, plus potential read-through from bipolar data into epilepsy and chronic pain, the platform offers meaningful multi-indication upside beyond the current pipeline.

Bears say

Rapport Therapeutics is a clinical-stage biotechnology company with no commercialized products, making its valuation highly dependent on the success of RAP-219 and earlier-stage nAChR programs rather than recurring revenue or established cash flow. The bear case is driven by significant binary clinical risk, including potential trial misses in focal onset seizures and bipolar mania, alongside the possibility of unexpected safety or tolerability issues that could materially impair development prospects. Additional downside stems from clinical and regulatory delays, step-therapy positioning, competitive threats, and ongoing financing risk until cash flow positive, all of which could pressure the stock before any meaningful de-risking occurs.

RAPP has been analyzed by 9 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Rapport Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

RAPP Analyst Forecast & Price Prediction

Get the latest RAPP stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in RAPP

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Rapport Therapeutics Inc (RAPP) Forecast

Analysts have given RAPP a Strong Buy based on their latest research and market trends.

According to 9 analysts, RAPP has a Strong Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $63.56, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $63.56, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Rapport Therapeutics Inc (RAPP)


RAPP Analyst Forecast & Price Prediction

Get the latest RAPP stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in RAPP

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover RAPP stock data and trends